| Patent(s) and the Corresponding Patented Drug(s) |
Top |
| World Intellectual Property Organization (WIPO) |
| Patent ID |
WO2012083092 |
| Title |
Bi-Dentate Compounds As Kinase Inhibitors. |
| Abstract |
The present disclosure provides compound having the general structure A or pharmaceutically acceptable salts thereof: Het-L-P (A) wherein Het is an aromatic moiety comprising a heterocyclic structure mimicking ATP, P is a docking site derived peptide or a docking site peptide rnimetic, and L is a linking moiety, wherein L links the ATP mimetic to the docking site peptide moiety. The compounds having the general structure A can serve as inhibitors of kinases, such as the kinases JNK, Erk and p38. |
| Applicant(s) |
Sanford-Burnham Medical Research Institute |
| Representative Drug(s) |
D08OJQ |
Drug Info
|
IC50 = 0.3 nM |
Click to Show More |
[1] |
|
2
|
D0Q8CR
|
Drug Info
|
IC50 = 0.9 nM
|
[1] |
|
3
|
D0G7LB
|
Drug Info
|
IC50 = 46 nM
|
[1] |
| Patent ID |
WO2010108155 |
| Title |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator. |
| Abstract |
This invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R is COOH or CH2OH. |
| Applicant(s) |
Vertex Pharmaceuticals Incorporated |
| Representative Drug(s) |
D08JIS |
Drug Info
|
IC50 = 4620 nM |
[1] |
